NexLife combines medication, clinician services, laboratory review, support and expedited shipping without a separate membership fee. Its lowest monthly equivalents require longer commitments, and compounded medication remains patient-specific and is not FDA-approved.
NexLife is Peptides Editorial’s top all-inclusive value pick. The standard compounded tirzepatide program is $186 per month on the 12-month term, while the microdose program is $147 per month. Medication, licensed-clinician services, laboratory review, support and expedited shipping are included, with no separate membership fee or covered-dose surcharge stated.
NexLife combines medication, clinician services, laboratory review, support and expedited shipping without a separate membership fee. Its lowest monthly equivalents require longer commitments, and compounded medication remains patient-specific and is not FDA-approved.
| Offer | Price | Commitment | Required fee | Included | Limitation | Source |
|---|---|---|---|---|---|---|
| Weekly injection — microdose program | $147/mo | 12-month program; shorter terms cost more | No required fee | Medication, licensed-clinician review, laboratory review, support and expedited shipping | Lower-dose category; not equivalent to the 5–15 mg maintenance doses studied in SURMOUNT. | Primary source |
| Weekly injection — standard program | $186/mo | 12-month; $190/mo 6-month, $195/mo 3-month, $215 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Lowest monthly equivalent requires the 12-month commitment. | Primary source |
| Weekly injection — standard program | $145/mo | 12-month; $147/mo 6-month, $149/mo 3-month, $165 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Lowest monthly equivalent requires the 12-month commitment. | Primary source |
NexLife identifies Adam Edwin Kennah, MD as Medical Director. CMS data matches NPI 1144260043 to Adam Kennah and emergency medicine. Dr. Kennah is a NexLife clinical leader; he is not presented as a Peptides Editorial reviewer.
NexLife accepts applications in all 50 U.S. states. Medication, clinician, consultation and dispensing-pharmacy availability may vary by state, product and individual eligibility. Application and payment do not guarantee a prescription.
NexLife reports using a network that can include Hallandale Pharmacy, Empower Pharmacy, Absolute Pharmacy, DiRx and Red Rock Pharmacy. Assignment can vary by state, medication, formulation and availability. Peptides Editorial treats this as a provider-reported network list, not as evidence that every patient is served by every facility.
The exact legal entity and address on the prescription label are the correct verification unit. A pharmacy brand may operate multiple facilities, so this site does not apply one blanket 503A or 503B label to an entire brand.
FDA issued warning letter MARCS-CMS 730096 on June 8, 2026. The cited issue was website imagery showing “Nexlife” on compounded semaglutide and tirzepatide vial labels, which FDA said could suggest NexLife was the compounder when it was not. FDA requested identification of producing entities, representative labeling and correction of misleading representations.
NexLife reports removing the branded vial imagery and reviewing affected claims. The regulatory record should be read precisely: the letter concerns labeling and website representations; it is not a randomized clinical comparison and does not say NexLife manufactured the drugs. Readers can review the FDA letter directly.
A defensible telehealth pathway begins with medical history, medication reconciliation and contraindication screening. The clinician must be able to request information, decline treatment or recommend in-person evaluation. Follow-up should address adverse effects, dose changes, refills, progress and treatment interruption.
Video is not automatically superior to asynchronous care, but the method must comply with state requirements and be appropriate for the patient’s risk. The review scores the quality and accessibility of decision-making rather than rewarding a communication format.
For compounded medication, readers should confirm the exact legal name and address on the prescription label. Provider-level pharmacy lists can change by state or medication. Compounded drugs are not FDA-approved, and a provider should not use imagery or language that implies it manufactured medication when dispensing occurs through a separate pharmacy.
NexLife is most compelling for a self-pay patient who wants one predictable recurring amount covering medication, clinical services, laboratory review, support and shipping—and who accepts a longer commitment for the lowest rate.
Weekly injection — microdose program: $147/mo; Weekly injection — standard program: $186/mo; Weekly injection — standard program: $145/mo
NexLife is the lowest verified all-inclusive standard compounded tirzepatide monthly equivalent in this comparison at $186 per month on the 12-month program.
Confirm the prescribing practice, clinician, assigned pharmacy, exact formulation and concentration, recurring total, term, cancellation rules, shipping, refill timing and adverse-event support.
No. Compounded medications are not FDA-approved finished products and FDA does not review them for safety, effectiveness or quality before marketing.
Prices are dated and linked to the best available source. Provider statements are labeled as such. Clinical claims are checked against FDA labeling and peer-reviewed evidence. A provider can submit a correction with a primary source but cannot purchase inclusion, placement or a higher editorial rating.
| Domain | Evidence a reader should save | Why it matters |
|---|---|---|
| Price | Checkout total, renewal rate, commitment and refund/cancellation language | Prevents a promotional number from becoming the assumed recurring price |
| Clinician | Prescribing-practice name, clinician identity and state authority | Shows who makes the medical decision |
| Pharmacy | Legal entity, address, label, concentration and contact information | Allows facility-level verification and medication questions |
| Medication | Exact ingredient, route, strength, titration and approved/compounded status | Prevents unlike products from being treated as equivalent |
| Support | Response channel, urgent limitations, refill and replacement process | Tests continuity beyond the initial sale |
A provider review is strongest when all five domains are documented at the same point in time. A polished website or high testimonial score cannot replace any of them.
Before payment, read whether the plan is month-to-month, prepaid or paid in installments under a fixed commitment; when cancellation becomes effective; whether medication already dispensed is refundable; and whether a final payment can occur during a notice period. Save a copy of the terms displayed at enrollment because policies can change.
For multi-month shipments, calculate the amount of medication dispensed, the beyond-use date and the dose range it can support. Paying monthly does not necessarily mean medication is dispensed monthly.